Ibio Inc IBIO

Healthcare Biotechnology

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

NYSEAM:IBIO - Post by User

Ibio Inc

Bullboard Posts

Post by garage64on Oct 11, 2014 3:15pm

148 Views

Post# 23021756

ibio égale remede miracle. Lundi en tres forte hausse. $$$$

Donne des Résultats Positif, l'infirmiere espagnol apres avoir pris du zmapp se porte mieu. ibio est essentiel pour le zmapp. le titre sur amex a bondit vendredi, ce n'est qu'un début, lundi le titre devraient exploser a plus de $ 2.50 a l'ouverture et meme plus

Bullboard Posts

The top 10 Canadian medical stocks